Dyadic International INC 8-K filings

Dyadic International has formalized an employment agreement with its Chief Financial Officer, Ping Rawson, outlining her compensation and terms of employment.

Dyadic International has amended its convertible note agreement, reducing the conversion price to $1.40 per share and setting new redemption dates.

Dyadic International reported its second quarter 2024 financial results, highlighting progress in alternative proteins, animal health, and human health sectors, along with a decrease in revenue and net loss compared to the same period last year.

Dyadic International has entered into a licensing and development agreement with Proliant Health & Biologicals for the production of recombinant serum albumin, including an upfront payment of $1.5 million and a share of profits.

Dyadic International has entered into a licensing and development agreement with Proliant Health & Biologicals for the production of recombinant serum albumin, including an upfront payment of $1.5 million and a share of profits.

Dyadic International held its 2024 Annual Meeting of Shareholders on June 11, 2024, with all proposals passing including the election of directors and ratification of the accounting firm.

Dyadic International reported its first quarter 2024 financial results, highlighting advancements in its C1 and Dapibus protein production platforms, including a successful Phase 1 clinical trial for its COVID-19 vaccine candidate.

Dyadic International announced leadership changes, including a new board chairman and COO, alongside its 2023 financial results and progress updates.

Dyadic International has raised $6 million through a private placement of convertible notes to accelerate revenue growth and commercialization efforts.